The IMBG has been studied in more than 250 patients (national and international studies, 11 centers, 5 countries (Europe & USA)), showing very positive results that have been presented in major international transplantation congresses. Also, pharmacoeconomic data shows that the use of the IMBG would entail significant savings to the Health Care systems.
The test has been clinically tested in patients after more than one year of the transplant. It can be used to identify and monitor patients at risk of rejection (who might require an increase of immunosuppression or a change in the immunosuppressive regime prescribed), and in patients with low risk to profit from a gradual reduction of immunosuppression and avoidance of severe side effects
The IMMUNOBIOGRAM® will be available in the European market in 2022 and in North America in 2023.